Table 3.

Drugs that target epigenetic regulation that have been approved or are in clinical trials

Drug	Epigenetic mechanisms	Phase	Disease	Reference or ClinicalTrials.gov identifier
Azacitidine	DNMTi	FDA approved	MDS	216
Guadecitabine	DNMTi	III	AML	NCT02920008
Entinostat	HDACi	III	breast adenocarcinoma	NCT02115282
Vorinostat	HDACi	FDA approved	CTCL	217
Romidepsin	HDACi	FDA approved	CTCL	216
Panobinostat	HDACi	FDA approved	multiple myeloma	218
Givinostat	HDACi	II	chronic myeloproliferative neoplasms	NCT01761968
Mocetinostat	HDACi	II	non-small cell lung cancer	NCT02954991
Valproic acid	HDACi	I	CLL	NCT00810680
Belinostat	HDACi	FDA approved	PTCL	219
CXD101	HDACi	I	advanced cancer	NCT01977638
MPT0E028	HDACi	I	advanced solid malignancies	NCT02350868
CPI-1205	EZH2 inhibitor	I	B cell lymphoma	NCT02395601
Tazemetostat	EZH2 inhibitor	II	diffuse large B cell lymphoma	NCT02875548

DNMTi, DNA methyltransferases inhibitor; FDA, US Food and Drug Administration; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; HDACi, histone deacetylases inhibitor; CTCL, cutaneous T cell lymphoma; CLL, chronic lymphocytic leukemia; PTCL, peripheral T cell lymphoma; EZH2, enhancer of zeste 2.